News

ReCor Medical Paradise System Renal Denervation RDN Therapy Hypertension

ReCor Medical advanced its Paradise System for renal denervation (RDN) for treatment resistant ...

SHEA Infection Control General Cardiology CT Systems White Coats

The Society for Healthcare Epidemiology of America (SHEA), an infection control organization, issued voluntary...

FDA Premarket Approval PMA Clinical Study EP Lab Cath Leads Implantable Devices

The U.S. Food and Drug Administration (FDA) has approved many cardiac implantable electronic device...

hypertension therapies cvrx barostim neo therapy

CVRx Inc. announced findings from a health-economic analysis published in the Journal of Hypertension that indicates Barostim Therapy is a cost-effective treatment option for...

Medtronic, symplicity, renal denervation

Medtronic Inc. announced its U.S. pivotal trial for its Symplicity renal denervation system to treat resistant hypertension, the SYMPLICITY HTN-3 trial, failed to meet its primary efficacy...

medtronic symplicity renal denervation therapy hypertension cath lab trial study

Medtronic Inc. announced that the first patients were randomized in Symplicity HTN-4, which will evaluate the Symplicity ...

medtronic symplicity spyral renal denervation cath lab hypertension treatment G3

Medtronic Inc. announced CE mark in Europe and Therapeutic Goods Administration (TGA) listing in Australia for its flexible 4 French multi-electrode Symplicity Spyral ...

Medtronic, Inc. presented three-year data from SYMPLICITY HTN-2, the first and longest-running randomized, controlled clinical trial of renal denervation, which continue to demonstrate results...

The 2014 Top 10 Health Technology Hazards list raises awareness of the potential dangers associated with the use of medical devices and helps healthcare providers minimize the risk of technology-...

renal stenting

The use of renal stenting in combination with medication-based therapy to treat hypertension showed no improvement in patient outcomes over the use of medications alone in treating hypertension....

Petr Neuzil, M.D., Nemocnice Na Homolce Hospital, Prague, Czech Republic, presented three-month results from the WAVE II study and complete six-month results for the WAVE I (first-in-man) at the...

renal denervation clinical trial study hypertension cath medtronic symplicity

Medtronic Inc. announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE), allowing the company to initiate SYMPLICITY HTN-4, the first...

blood pressure monitors stroke treatment devices hypertenion therapies cath lab

A new way of using blood pressure-lowering medications could prevent more than a fourth of heart attacks and ...

Medtronic Inc. announced U.S. Food and Drug Administration (FDA) approval of its Lead Integrity Alert (LIA) software for use with non-Medtronic ...

renal denervation clinical trial study hypertension vessix boston scientific

Patients treated with the Boston Scientific Vessix Renal Denervation System experienced a significant and...

renal denervation therapy hypertension kona medical morningside

Kona Medical Inc. announced it has closed a Series D equity financing of $10 million. Morningside Group, a broad-based investment firm with significant presence in China, led the investment and is...

renal denervation, Symplicity

Since its debut in 2010, the renal denervation market has generated enthusiasm across the medical device...

cath lab cardiovascular surgery clinical trial/study scai heart attack

The Society for Cardiovascular Angiography and Interventions (SCAI) assembled  a panel that has proposed new criteria for identifying patients who experience a heart attack after coronary...

Rox Medical has crossed the halfway point in the CONTROL-HTN international, multi-center, randomized controlled hypertension trial. The milestone was met with the enrollment of the first patient...

A new study of patients who died of sudden cardiac arrest, a usually fatal condition that causes the heart to stop beating, shows the majority who qualified to receive potentially lifesaving...